Published in final edited form as:

ACS Chem Neurosci. 2018 May 16; 9(5): 1001–1013. doi:10.1021/acscchemneuro.7b00422.

1,2,3-Triazole Rings as a Disulfide Bond Mimetic in Chimeric AGRP-Melanocortin Peptides: Design, Synthesis, and Functional Characterization

Srinivasa R. Tala[†], Anamika Singh[†], Cody J. Lensing[†], Sathya M. Schnell[†], Katie T. Freeman[†], James R. Rocca[‡], and Carrie Haskell-Luevano^{†,*}

[†]Department of Medicinal Chemistry and the Institute for Translational Neuroscience, University of Minnesota, Minneapolis, Minnesota 55455, United States

[‡]Advanced Magnetic Resonance Imaging and Spectroscopy, McKnight Brain Institute, University of Florida, Gainesville, Florida 32610, United States

Abstract

The melanocortin system is involved in the regulation of complex physiological functions, including energy and weight homeostasis, feeding behavior, inflammation, sexual function, pigmentation, and exocrine gland function. The five melanocortin receptors that belong to the super family of G protein-coupled receptors (GPCRs) are regulated by endogenously expressed agonists and antagonists. The aim of the present study was to explore the potential of replacing the disulfide bridge in chimeric AGRP-melanocortin peptide Tyr-c[Cys-His-DPhe-Arg-Trp-Asn-Ala-Phe-Cys]-Tyr-NH₂ (**1**) with 1,2,3-triazole moieties. A series of 1,2,3-triazole bridged peptidomimetics were designed, synthesized, and pharmacologically evaluated at the mouse melanocortin receptors. The ligands possessed nanomolar to micromolar agonist cAMP signaling potency. A key finding was that the disulfide bond in peptide **1** can be replaced with the mono-triazole ring with minimal effect on the functional activity at the melanocortin receptors. The 1,5-disubstituted triazole bridged peptide **6** showed equipotent functional activity at the mMC3R and modest 5-fold decreased agonist potency at the mMC4R compared to **1**. Interestingly, the 1,4- and 1,5-disubstituted isomers of the triazole ring resulted in different selectivities at the receptor subtypes indicating subtle structural features that may be exploited in the generation of selective melanocortin ligands. Introducing cyclic and acyclic bis-triazoles moieties in the chimeric-AGRP template **1** generally decreased agonist activity. These results will be useful for further design of neuronal chemical probes for the melanocortin receptors as well as in other receptor systems.

*Corresponding Author: Carrie Haskell-Luevano, Ph.D. Department of Medicinal Chemistry and Institute for Translational Neuroscience, University of Minnesota, 308 Harvard Street SE, Minneapolis, Minnesota, 55455, United States; chaskell@umn.edu; Phone: 612-626-9262; Fax: 612-626-3114.

SUPPORTING INFORMATION

Analytical data of the peptides and NMR spectra of the 1,4- and 1,5-disubstituted triazole-bridge peptides **3** and **6** are reported in the supporting information.

Author Contributions: S.R.T. and C.H.-L. designed the research. S.R.T., A.S., S.M.S., and K.T.F. performed the experiments. J.R. acquired NMR spectra. S.R.T., A.S., and C.H.-L. analyzed the data. S.R.T. wrote the manuscript with the help of A.S., C.J.L., and C.H.-L.

Conflict of Interest: The authors declare no competing financial interests.

Table of Contents Graphic

Keywords

Melanocortin receptors; AGRP; peptidomimetic; triazoles; disulfide bond

INTRODUCTION

The melanocortin receptors (MCRs) are all G protein-coupled receptors (GPCRs) that signal mainly through the Gα_s pathway to increase the amount of intracellular cAMP.¹ The melanocortin system includes five receptors (MC1-5R),^{2–8} endogenous agonists [α-melanocyte stimulating hormones (MSH), β-MSH, γ-MSH, and adrenocorticotrophic hormone (ACTH)], and antagonists [agouti-signaling protein (ASP)⁹ and agouti-related protein (AGRP)].¹⁰ The melanocortin-1 receptor (MC1R) is expressed peripherally and is involved in skin and hair pigmentation.^{2, 3} The melanocortin-2 receptor (MC2R) is stimulated only by the ACTH and is expressed in the adrenal cortex to regulate steroidogenesis.³ The melanocortin-3 receptor (MC3R) is expressed in several tissues including the gut, placenta, heart, and brain and is involved in metabolism and energy homeostasis.^{4, 6, 11, 12} The melanocortin-4 receptor (MC4R) is expressed primarily in the brain and regulates feeding behavior, energy homeostasis, and sexual function.^{5, 7, 13, 14} The melanocortin-5 receptor (MC5R) is expressed in a wide variety of tissues, both centrally and peripherally, and is involved in exocrine gland function in mice.^{8, 15}

The endogenous agonists α-MSH, β-MSH, γ-MSH, and ACTH are derived from posttranslational modifications of the proopiomelanocortin (POMC) protein.^{16, 17} All of these endogenous melanocortin linear peptides share a core “His-Phe-Arg-Trp” tetrapeptide sequence that has been hypothesized to be important for melanocortin receptor molecular recognition and stimulation.^{18–20} The development of probes based on the His-Phe-Arg-Trp sequence targeting the neuronal MC3R and MC4R has been of specific interest to both the industrial and academic communities.²¹ Specifically, melanocortin agonists produce anorexigenic effects via the neuronal MC3R and MC4R when administered intracerebroventricularly (i.c.v.) in mice, and therefore, may have utility in the treatment of metabolic disorders.^{13, 22}

In the current study, chimeric peptides based on the His-Phe-Arg-Trp sequence in an AGRP-scaffold are studied. The MC3R and MC4R antagonist AGRP is produced in the brain and has been demonstrated to stimulate feeding and decrease energy expenditure.^{23–27} Human AGRP is a 132 amino acid protein containing a cysteine-rich C-terminal domain.¹⁰ Similar

to the core sequence in the endogenous agonists, melanocortin antagonists possess a core “Arg-Phe-Phe” tripeptide sequence that has been demonstrated to be important for binding and function.^{28, 29} The C-terminal domain of AGRP has previously been shown to exhibit equipotent binding and activity compared with the full length peptide.^{10, 30} Further truncation typically result in diminished activity, however, a recent report of AGRP-derived peptides designed to mimic the active β -hairpin secondary structure resulted in sub-nanomolar antagonist activity at the mMC4R and was 160-fold selective for the mMC4R versus the mMC3R.³¹

The AGRP derivative, hAGRP(109–118) (Tyr-c[Cys-Arg-Phe-Phe-Asn-Ala-Phe-Cys]-Tyr-NH₂), was previously shown to have modest antagonist activity at the MC3R and MC4R.^{29, 32, 33} However, replacing the Arg-Phe-Phe with the agonist scaffold His-DPhe-Arg-Trp resulted in the sub-nanomolar potent agonist **1** (Tyr-c[Cys-His-DPhe-Arg-Trp-Asn-Ala-Phe-Cys]-Tyr-NH₂) at the melanocortin receptors.^{34–37} Replacement of the disulfide bond with a lactam bridge, Tyr-c[β -Asp-His-DPhe-Arg-Trp-Asn-Ala-Phe-Dpr]-Tyr-NH₂, resulted in a full agonist at the melanocortin receptors that was as potent as the endogenous α -MSH agonist.³⁴ Incorporation of a bioactive reverse-turn heterocycle into this template resulted in analogues with nanomolar potency at the mMC1R and MC3-5R,³⁸ a selective antagonist at MC3R,³⁹ and a selective and stable agonist of MC4R.⁴⁰ Hence, rational design of AGRP chimeric ligands may allow the development of potent and potentially selective ligands for the melanocortin receptors and may lead to novel chemical probes and possible therapeutic agents at the neuronal melanocortin receptors (*i.e.* MC3R and MC4R).

Disulfide bonds play important roles in the structure, stability and biological function of endogenous proteins and peptides.⁴¹ However, the disulfide bond is rather unstable in reducing environments or in the presence of certain enzymes which can lead to structural rearrangements or low metabolic stability that lowers *in vivo* activity.^{42, 43} Stable covalent bond peptidomimetics such as lactam-bridges,⁴⁴ thioethers,⁴⁵ olefins or carbon-carbon double bonds,^{46, 47} and diselenides⁴⁸ have been reported as replacements for disulfide bonds. However, some of these mimetic moieties result in lower bioactivity or include complex chemistry.⁴⁹ For example, the lactam-bridge cyclized variants require orthogonal protecting strategies to keep the N-terminal protected while cyclization occurs through the side chains of aspartic acid and lysine residues. The multiple protection and deprotection steps result in an overall decrease in synthetic yield.

Utilization of the 1,2,3-triazole moiety as a disulfide bond replacement in peptide chemistry was first reported by Meldal *et al.*⁵⁰ The chemical orthogonality of the azide and alkyne building blocks, the robust synthetic methodology using click chemistry via either a copper (CuAAC)^{51–53} or a ruthenium catalyzed cycloaddition (RuAAC),^{54, 55} the hydrogen bonding capabilities, and the increased water solubility make the triazole moiety an attractive template for designing novel bioactive analogues. Moreover, 1,2,3-triazole containing compounds have previously exhibited increased metabolic stability presumably through increased stability to isomerases or proteases.^{56, 57}

There have been various examples in the literature of the successful use of triazole bridged peptides in ligand design. For example, a triazole-bridged peptide mimicking the epidermal

growth factor receptor (EGFR) dimerization arm was reported to be resistant to proteolytic degradation while maintaining secondary structural characteristics.⁵⁸ Through the careful selection of triazole-bridge length, β -hairpin peptides were generated that inhibited acyl peptide hydrolase (APEH) enzyme activity.^{59, 60} More specifically, there have been several reports of the utilization of 1,4-disubstituted and 1,5-disubstituted triazole-bridges as a disulfide bond replacement.^{50, 61–63} Replacement of a disulfide bond by 1,5-disubstituted triazole-bridge was reported for the sunflower trypsin inhibitor-I.⁶³ The resulting 1,5-disubstituted triazole-bridged analogue retained nearly full biological activity in contrast to its 1,4-disubstituted triazole-bridged analogue. Importantly for the current study, incorporation of 4,1 or 1,4-disubstituted triazole-bridges as replacement of lactam-bridge in melanocortin agonist MT-II resulted in potent agonist ligands at the mMC1R, mMC3R, mMC4R, and mMC5R.⁶⁴

The objective of the current study was to investigate the effects of replacing the disulfide bond in the AGRP chimeric peptide **1** (Figure 1a) with various triazole-based templates. It was hypothesized that the triazole-bridge can mimic the disulfide-bridge in **1** and may rigidify the backbone to result in potent and/or selective melanocortin ligands. Herein, the incorporation of 1,4- and 1,5-disubstituted triazole-bridges as a replacement of disulfide bond in the AGRP chimeric peptide template (**1**) is reported along with the synthesis of additional acyclic and cyclic bis-triazole containing ligands. These compounds were pharmacologically assessed at the mMC1R, mMC3R, mMC4R, and mMC5R. These new chemical probes will be useful to study the effects of the neuronal MC3R and MC4R on energy homeostasis. Also the synthetic SAR lessons learned are broadly applicable to future design of neuronal chemical probes for other receptor systems.

RESULTS AND DISCUSSION

Design and Synthesis of Triazole Containing Peptides

Previously, the AGRP chimeric peptide template Tyr-c[Cys-His-DPhe-Arg-Trp-Asn-Ala-Phe-Cys]-Tyr-NH₂ (**1**) was identified as a sub-nanomolar agonist for the melanocortin receptors.^{34–37} Peptide **1** is derived from the active β -hairpin loop of hAGRP(109–118) decapeptide sequence within the C-terminal region, but replaces the key antagonist pharmacophore residues Arg-Phe-Phe to the potent melanocortin agonist scaffold His-DPhe-Arg-Trp.^{34–37} This peptide is cyclized through a single disulfide bridge between two Cys side chains (Figure 1a). Peptide **1** is equipotent to the synthetic and potent agonist NDP-MSH at the centrally located mMC4R (Table 1).^{34–37} NDP-MSH is a common melanocortin control peptide that decreases food intake upon central administration in mice. The similar potency of peptide **1** to NDP-MSH suggests it may be valuable scaffold to develop chemical probes to study the neuronal melanocortin receptors.¹³ In the current study, the possibility of a triazole-bridge as a replacement for the disulfide-bond in the melanocortin chimeric peptide **1** is explored.

The 1,4-disubstituted and 1,5-disubstituted triazole-bridged cyclic peptides **3** and **6** were designed from the original chimeric peptide **1** by replacing the disulfide bond with the triazole-bridges (Schemes 1 and 2). First, linear peptide Tyr-Aza-His-DPhe-Arg-Trp-Asn-

Ala-Phe-Pra-Tyr-NH₂, **2**, was synthesized in which the *N*^α-Fmoc-Cys-OH residues were replaced by *N*^α-Fmoc-L-Pra-OH and *N*^α-Fmoc-L-Aza-OH amino acids during synthesis (Scheme 1, Figure 1). This resulted in peptide **2** with side chains containing alkyne and azide groups, respectively. The stepwise solid-phase assembly of the linear peptide **2** was performed following the Fmoc/*t*Bu SPPS strategy on Rink-amide MBHA resin.⁶⁵ The linear peptide **2** was then cyclized using Cu(I)-catalyzed intramolecular azide-alkyne cycloaddition in solution to afford the 1,4-disubstituted triazole-bridged cyclic peptide **3** (Scheme 1).

The 1,5-disubstituted triazole-bridged cyclic peptide **6** was also synthesized using Fmoc-SPPS on Rink-amide MBHA resin (Scheme 2). First, amino acids were coupled on resin to give linear peptide resin **4**, which was then cyclized on resin using chloro(pentamethylcyclopentadienyl)(cyclooctadiene)ruthenium (II) under microwave conditions (60 °C, 30 W, 3 h) to afford macrocyclized peptide **5** on resin. Further coupling of Tyr and cleavage yielded 1,5-substituted triazole-bridged cyclic peptide **6** (Scheme 2). The purity of peptides **2**, **3**, and **6** was confirmed by RP-HPLC and mass was determined by ESI-MS (Supporting Information). Since there is no change in the molecular mass between linear peptide **2** and the triazole-bridged peptides **3** and **6**, IR spectra was recorded for peptides **2**, **3**, and **6** to confirm the formation of the triazole-bridge. Linear peptide **2** gave an IR absorption band around 2100 cm⁻¹ supporting the presence of an azide group. Absence of this band in peptides **3** and **6** supports the consumption of azide groups and formation of triazole-bridges in these peptides (Supporting Information).^{63, 66, 67}

The 1,4- and 1,5-substitution pattern in peptides **3** and **6** was confirmed using 2D-HSQC NMR spectroscopy studies by measuring the chemical shifts of the ¹H and ¹³C coupling signal assigned to the unique carbon-bonded proton found in both heterocycles. In the ¹H-NMR spectra, the carbon-bonded proton in the 1,4-disubstituted triazole appeared at 7.52 ppm, whereas this proton in the 1,5-disubstituted triazole appeared at 7.39 ppm (Supporting Information). The proton bonded carbon in the 1,4-disubstituted triazole appeared at 124.6 ppm, where as in 1,5-disubstituted triazole it appeared at 132.6 ppm in the 2D-HSQC NMR spectroscopic studies (Supporting Information). The measured ¹H and ¹³C chemical shifts were in good agreement with previously reported data^{63, 68} and displayed a significant difference between the 1,4-disubstituted triazole and 1,5-disubstituted triazole patterns (Supporting Information).

Previously, bulky side chains were used to synthesize conformationally constrained analogs to modulate potency and selectivity at the melanocortin receptor subtypes.⁶⁹ To modify the selectivity of triazole-bridged peptides at the melanocortin receptors, we designed bis-triazole-bridged macrocyclic peptides **8** and **11** (Scheme 3 and 4) that we envisioned would be more bulky and rigid than mono-triazole-bridged macrocyclic peptides **3** and **6**. First to synthesize 1,4-substituted bis-triazole-bridged peptide **8**, linear peptide **7** was synthesized using Fmoc-SPPS on Rink-amide MBHA resin in which both Cys amino acids were substituted with *N*^α-Fmoc-L-Aza-OH in the lead chimeric peptide template **1**. The linear peptide **7** on reaction with 1,3-diethynylbenzene using a slightly modified Cu(I)-catalyzed intermolecular azide-alkyne cycloaddition previously reported did not afford the expected 1,4-disubstituted bis-triazole-bridged macrocyclic peptide **8**.⁷⁰ Instead, the 1,4-substituted

bis-triazole containing acyclic peptide **9** was isolated as the major product along with unreacted peptide **7** (Scheme 3). In order to synthesize the 1,5-substituted bis-triazole containing acyclic peptide **12** on the same template, we first synthesized a peptide intermediate **10** on Rink-amide MBHA resin using the Fmoc/*t*Bu SPPS approach in which both Cys amino acids were again replaced with *N*^α-Fmoc-L-Aza-OH. Then the peptide on resin (**10**) was treated with 1,3-diethynylbenzene using chloro(pentamethylcyclopentadienyl)-(cyclooctadiene)ruthenium (II) under microwave conditions (60 °C, 30 W, 3 h). Deprotection, cleavage, and purification of the peptide led to the purified 1,5-disubstituted bis-triazole-acyclic peptide **12** as the major product. Again in this case, we did not isolate the expected 1,5-disubstituted bis-triazole-bridged macrocyclic peptide **11**. These results suggested that the formation of the macrocyclic peptides is not feasible under current reaction conditions possibly due to the ring size and steric effects.

To study the effects of ring size on macrocyclization, *N*_α-Fmoc-L-Orn(N₃)-OH was utilized to replace the *N*^α-Fmoc-L-Aza-OH in the reaction (Figure 1). The use of *N*^α-Fmoc-L-Orn(N₃)-OH spaces the azide group from the peptide backbone by two extra methylene units compared to *N*^α-Fmoc-L-Aza-OH which should reduce the steric hindrance of the desired reaction. First, linear peptide **13** was synthesized by replacing the two Cys amino acids in **1** with *N*^α-Fmoc-L-Orn(N₃)-OH using the Fmoc/*t*Bu SPPS approach (Scheme 5). Linear peptide **13** was reacted with 1,3-diethynylbenzene using Cu(I)-catalyzed intermolecular azide-alkyne cycloaddition to yield the macrocyclic 1,4-disubstituted bis-triazole-bridged peptide **14** as the major product (Scheme 5).

The 1,5-substituted bis-triazole peptide regioisomer of **14** was also synthesized (Scheme 6). The intermediate peptide resin **15** was treated with 1,3-diethynylbenzene using chloro(pentamethylcyclopentadienyl)-(cyclooctadiene)ruthenium (II) under microwave conditions (60 °C, 30W, 3 h). The deprotection, cleavage, and purification of the peptide resulted in the 1,5-disubstituted bis-triazole-macrocyclic peptide **16** as the major product (Scheme 6). These results suggest that the formation of the macrocyclic peptide under current reaction conditions is dependent on steric effects in which increased ring size or additional spacing to separate the azide from the peptide backbone is a requirement for efficient cyclization.

Pharmacological Evaluation

The ability of the synthesized compounds (Table 1) to stimulate intracellular cAMP signaling was assayed in HEK293 cells stably expressing the cloned mouse (m)MC1R, mMC3R, mMC4R, and mMC5R using AlphaScreen cAMP Assay Technology (Perkin Elmer).^{71, 72} The mMC2R is only stimulated by ACTH and was therefore excluded in this study. Due to the inherent error of the assay (in our hands), peptides that were within a 3-fold potency range were considered to be equipotent.

The agonist EC₅₀ values at the mouse melanocortin receptors of compounds **2**, **3**, and **6** (as well as control compounds NDP-MSH and compound **1**) are summarized in Table 2 and Figure 2. The linear compound **2** containing azide and alkyne groups in place of thiols resulted in 400-, 23-, 46-, and 8-fold decreased agonist potency at the mMC1R, mMC3R,

mMC4R, and mMC5R, respectively, compared to control compound **1**. The covalent bond formation via click chemistry between azide and alkyne group resulted in the triazole bridged compounds **3** and **6**. Cyclized peptide **3**, which contained a 1,4-disubstituted triazole ring, resulted in 41-, 13-, 14- and 7-fold decreased activity at the mMC1R, mMC3R, mMC4R and mMC5R, respectively, when compared to the cyclic disulfide compound **1**. Compound **3** had increased functional potency at the mMC1R and mMC4R in comparison to the linear compound **2** suggesting that cyclization is important for the activity at these two receptor isoforms. The cyclic 1,5-disubstituted compound **6** resulted in 29- and 5-fold decreased activity at the mMC1R and mMC4R, respectively, compared to compound **1**. Compound **6** was within experimental error at the mMC3R and mMC5R compared to compound **1**. Interestingly, peptide **6** increased potency at the mMC3R and mMC5R and maintained potent nanomolar agonist activity at the mMC1R and mMC4R when compared to the compound **3** suggesting the type of triazole-linkage (*i.e.* 1,4-disubstituted vs. 1,5-disubstituted) can modify functional activity.

In linear peptides **9** and **12**, both cysteine residues were replaced by either 1,4-disubstituted (3-ethenylphenyl)-triazole or 1,5-disubstituted (3-ethenylphenyl)-triazole groups mMC4R, and mMC5R using AlphaScreen cAMP Assay Technology (Perkin Elmer).^{71, 72} The mMC2R is only stimulated by ACTH and was therefore excluded in this study. Due to the inherent error of the assay (in our hands), peptides that were within a 3-fold potency range were considered to be equipotent.

The agonist EC₅₀ values at the mouse melanocortin receptors of compounds **2**, **3**, and **6** (as well as control compounds NDP-MSH and compound **1**) are summarized in Table 2 and Figure 2. The linear compound **2** containing azide and alkyne groups in place of thiols resulted in 400-, 23-, 46-, and 8-fold decreased agonist potency at the mMC1R, mMC3R, mMC4R, and mMC5R, respectively, compared to control compound **1**. The covalent bond formation via click chemistry between azide and alkyne group resulted in the triazole bridged compounds **3** and **6**. Cyclized peptide **3**, which contained a 1,4-disubstituted triazole ring, resulted in 41-, 13-, 14- and 7-fold decreased activity at the mMC1R, mMC3R, mMC4R and mMC5R, respectively, when compared to the cyclic disulfide compound **1**. Compound **3** had increased functional potency at the mMC1R and mMC4R in comparison to the linear compound **2** suggesting that cyclization is important for the activity at these two receptor isoforms. The cyclic 1,5-disubstituted compound **6** resulted in 29- and 5-fold decreased activity at the mMC1R and mMC4R, respectively, compared to compound **1**. Compound **6** was within experimental error at the mMC3R and mMC5R compared to compound **1**. Interestingly, peptide **6** increased potency at the mMC3R and mMC5R and maintained potent nanomolar agonist activity at the mMC1R and mMC4R when compared to the compound **3** suggesting the type of triazole-linkage (*i.e.* 1,4-disubstituted vs. 1,5-disubstituted) can modify functional activity.

In linear peptides **9** and **12**, both cysteine residues were replaced by either 1,4-disubstituted (3-ethenylphenyl)-triazole or 1,5-disubstituted (3-ethenylphenyl)-triazole groups and were derived from the linear analogues **7** and **10**, respectively. Linear peptide **7** with azide side chains in place of the thiols showed 36-, 27-, 37-, and 8-fold decreased potency at the

mMC1R, mMC3R, mMC4R, and mMC5R, respectively, compared to control cyclic compound **1** (Table 3). The activities of compound **7** were similar at the mMC3R, mMC4R, and mMC5R compared to the similar linear compound **2**, which displays azide and alkenyl side chains. However, peptide **7** resulted in 12-fold decreased potency at the mMC1R compared to peptide **2**. The linear peptides **9** and **12** both showed significantly decreased potencies compared to **1**. Peptide **9** resulted in 5728-, 665-, 3540-, and 144-fold decreased agonist potency compared to compound **1** at the mMC1R, mMC3R, mMC4R, and mMC5R, respectively (Table 3). The 1,5-disubstituted analogue **12** was more potent than **9**, but still had 829-, 184-, 330, and 45-fold decreased potencies compared to compound **1** at the mMC1R, mMC3R, mMC4R, and mMC5R, respectively (Table 3).

The macrocyclic peptides **14** and **16** were derived from the linear analogues **13** and **15**, respectively, and showed improved potency compared to the linear counterparts **8** and **9** (Table 4). Like the cyclic mono-triazoles and linear bis-triazole, the 1,5-disubstituted bis-triazole peptide **16** was either equipotent or had increased potency compared to the 1,4-disubstituted bis-triazole peptide **14**. Interestingly, peptides **14** and **16** showed modest selectivity for the mMC5R with EC₅₀ values of 36 nM and 80 nM, respectively (Table 4).

CONCLUSIONS

In the present study, we have designed and synthesized a series of click-generated triazole containing cyclic or acyclic peptidomimetics to probe potency and selectivity at the melanocortin receptors. These peptidomimetics will be useful probes to study the various physiological functions including feeding behavior, energy homeostasis, sexual function, pigmentation, and cardiovascular function. Specifically, these probes can be used to study the neuronal MC3R and MC4R and their effects on energy homeostasis as their structure was based AGRP, the endogenous antagonist of these receptors. The previously reported 11-mer peptide **1** was the starting scaffold of the current study. Peptide **1** is based on the structure of hAGRP(109–118) containing one disulfide bond between the cysteine residues as well the substitution of the antagonist scaffold Arg-Phe-Phe to the agonist scaffold His-DPhe-Arg-Trp.^{34–37} This potent agonist peptide is not selective at the melanocortin receptors and the disulfide bond may be a metabolic liability that reduces its utility as *in vivo* probe. Triazoles were selected for replacing the disulfide bond due to their high dipole moment, chemical orthogonality, conformational stability, and ease of synthesis. Triazole rings are aromatic in nature and can participate in hydrogen bonding, which can facilitate additional putative ligand-receptor interactions and provide distinct functional properties.^{50–64}

Of the novel chemical probes synthesized in this study, the mono-triazole compound **6** was the most potent compound with equipotent activity (within 3-fold experimental error) at the mMC3R and mMC5R and modest 5-fold decreased agonist potency at the mMC4R compared to the disulfide containing peptide **1**. It also resulted in a 29-fold decrease in agonist potency at the mMC1R that may help give it increased utility as a chemical probe for the neuronal mMC3R and mMC4R. This reduced potency at the mMC1R was similar to the previous report of a 1,4-substituted triazole containing MT-II analogue.⁶⁴ The disulfide peptide **1** showed some discrimination in potency being 5- to 10-fold more potent at the mMC1R and mMC4R versus the mMC3R and mMC5R. This difference was lost when the

1,5-disubstituted triazole ring replaced the disulfide bridge in compound **6**. Compound **3** possessed 5-fold selectivity for the mMC4R versus the mMC3R, but in general resulted in 7- to 40-fold decreased agonist potency compared to peptide **1**. The linear precursor **2** was less potent than the cyclic peptides **3** and **6** suggesting that the macrocyclization of the peptide via the triazole ring contributed to the stability of the bioactive conformation resulting in improved agonist activity.

The acyclic peptides **9** and **12** resulted from unsuccessful cyclizations of precursors **7** and **10** with bulky 1,4-disubstituted (3-ethenylphenyl)-triazole and 1,5-disubstituted (3-ethenylphenyl)-triazole groups. Both **9** and **12** showed reduced potency compared to their mono-triazole counterpart. The 1,5-disubstituted peptide **12** was more potent at all studied melanocortin receptors than the 1,4-disubstituted peptide **9**. This result can be explained by conformational studies of 1,4- and 1,5-substituted triazole rings previously reported.⁷³ The 1,4-disubstituted triazole moiety is flexible without preference for a particular conformation, whereas, the 1,5-disubstituted triazole exists in a number of stable and structurally diverse conformers which may lead to several secondary structures including turns.⁷³ Our data suggests that the 1,5-disubstituted triazole ring is preferred presumably because it is achieving a structural conformation that is better suited to activate the melanocortin receptors than those achieved by the 1,4-disubstituted triazole.

Peptides **14** and **16** are cyclic bis-triazoles based on a two-component system linked by a phenyl ring linker. Unlike linear precursor **7**, which had an azidomethyl group, peptide **13** had azidopropyl groups in place of the cysteine residues. This modification resulted in reduced agonist potency of linear peptide **13** at all melanocortin receptors. The mMC1R and mMC4R were more affected with *c.a.* 1000-fold decreased potency, while the mMC3R resulted in 300-fold decreased agonist potency compared to **1**. However, at the mMC5R both peptides **7** and **13** possessed only 8- and 15-fold, respectively, decreased agonist potency compared to **1**. Cyclization of the linear precursor **13** via the phenyl linker into the 1,4-disubstituted bis-triazole, **14**, and its 1,5-counterpart, **16**, did not improve activity. In fact, activity was reduced at all the melanocortin receptors except for compound **16** at the mMC5R, which was equipotent compared to the linear precursor **13**. It may be hypothesized that the bis-triazole moiety with the phenyl linker altered the size of the ring and perturbed a favorable conformation inhibiting important ligand-receptor interactions at the mMC1R, mMC3R, and mMC4R.

In summary, we have designed, synthesized, and pharmacologically evaluated three series of triazole containing peptides as possible replacements for the disulfide-bridge in an AGRP chimeric peptide template as agonists at the mouse melanocortin receptors. The modular synthesis of 1,4-disubstituted triazole bridged peptides was obtained using copper-catalyzed azide-alkyne “click” cycloaddition (CuAAC) in solution phase. The 1,5-disubstituted triazole-bridged peptides were obtained using ruthenium(II)-catalyzed azide-alkyne cycloaddition (RuAAC) on solid-phase using microwave irradiation. Peptide **6** having a 1,5-disubstituted triazole-bridge showed similar potency at the mMC3R and mMC5R, and 5-fold decreased potency at the mMC4R compared to the disulfide-bridged peptide **1** supporting its further development as neurochemical probe. The macrocyclization involving bis-triazoles resulted compound **16** that is a potent agonist of the mMC5R with 80 nM

agonist potency. It can be postulated that the metabolic stability of these compounds will be improved by the replacement of the disulfide bridge with the triazole moiety due the inherent redox stability of triazoles and the lack of specific enzymes to degrade the unnatural triazole linker. We demonstrated that disulfide bond replacement with a triazole-bridge is a valid strategy for engineering melanocortin peptides, and we provided the field with novel chemical probes to study the neuronal melanocortin receptors.

METHODS

Chemistry

All chemicals were obtained from commercial suppliers and were used without further purification. The amino acids N_{α} -9-fluorenylmethoxycarbonyl (Fmoc)-Cys(Trt)-OH, Fmoc-Tyr(*t*Bu)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-His(Trt)-OH, Fmoc-Trp(Boc)-OH, Fmoc-DPhe-OH, Fmoc-Phe-OH, Fmoc-Asn(Trt)-OH, Fmoc-Ala-OH, Rink amide *p*-methylbenzhydrylamine resin (*p*-MBHA resin, 0.35 mequiv/g substitution), and coupling reagent *O*-benzotriazole- N,N,N',N' -tetramethyl-uronium-hexafluoro-phosphate (HBTU) were purchased from Peptides International (Louisville, KY). The amino acids N_{α} -(9-fluorenylmethoxycarbonyl)-propargylglycine-OH (Fmoc-L-Pra-OH), N_{α} -(9-fluorenylmethyl-oxycarbonyl)-3-azido-L-alanine (Fmoc-L-Aza-OH) and tris(3-hydroxypropyl triazolylmethyl)-amine, 1,3-diethynylbenzene, chloro(pentamethylcyclopentadienyl)(cyclooctadiene)-ruthenium (II) were purchased from Sigma-Aldrich (St. Louis, MO). N_{α} -(9-fluorenylmethyl-oxycarbonyl)-azido-L-Ornithine (Fmoc-L-Orn(N_3)-OH) was synthesized according to literature procedure.⁷⁰ Copper sulfate pentahydrate was purchased from Chem-Impex International Inc. (Wood Dale, IL). Sodium ascorbate and *t*-butanol were purchased from Acros Organics (New Jersey, USA).

Dichloromethane (DCM), methanol (MeOH), acetonitrile (ACN), and anhydrous ethyl ether were purchased from Fisher (Fair Lawn, NJ). *N,N*-Dimethylformamide (DMF), trifluoroacetic acid (TFA), 1,3-diisopropylcarbodiimide (DIC), and piperidine were purchased from Sigma (St. Louis, MO). *N,N*-Diisopropylethylamine (DIEA) was purchased from Aldrich (Milwaukee, WI). All reagents and chemicals were ACS grade or better and were used without further purification.

Solid Phase Peptide Synthesis Using Microwave Irradiation

The Rink-amide MBHA resin was transferred into a 25 mL polypropylene reaction vessel (CEM) and swelled in dichloromethane for 1 h. The bottom cap of the vessel was removed and the vessel was transferred onto a vacuum filtration manifold. Deprotection of the Fmoc group was achieved using 20% piperidine in DMF for 2 min at room temperature, followed by irradiating the reaction mixture at 75 °C, 30 W for 4 min in a CEM Discover SPSTM instrument. After cooling and washing the resin with DMF (4×), a ninhydrin Kaiser test was performed.⁷⁴ The amino acid coupling step was performed under the microwave conditions (75 °C, 30 W) for 5 min. The Fmoc protected amino acid (3 equiv.) and HBTU (3 equiv.) were dissolved in DMF and added to the reaction vessel followed by addition of DIEA (5 equiv.). The coupling of the Cys and His amino acids were performed at lower temperatures (50 °C, 30 W) for 5 mins. To ensure coupling of Arg, equivalents were increased to 5 equiv.

of Arg and 7 equiv. of DIEA and the reaction time was increased to 10 min. The reagents were mixed by bubbling nitrogen gas into the reaction vessel. The iterative process of the Fmoc deprotection/coupling cycle was performed to elongate the peptide chain. After the final deprotection, the peptide was cleaved from the resin using the cleavage cocktail TFA/anisole/1,2-ethanedithiol/phenol/H₂O (91:2.5:2.5:1.5:2.5 v/v/v/v/v) at room temperature for 3 h. After the simultaneous cleavage and side chain deprotection, the solution was concentrated. The peptide was precipitated from the solution and washed using cold (4 °C) anhydrous diethyl ether.

The crude peptides were purified by reverse-phase (RP-)HPLC (flow rate of 5 mL/min, acetonitrile/water 0.1% TFA) using a Shimadzu chromatography system with a photodiode array detector and a semi-preparative RP-HPLC C18 bonded silica column (Vydac 218TP1010, 1.0×25 cm). The purified peptides were >95% pure as determined by RP-HPLC in two diverse solvent systems (*i.e.* MeOH and ACN) (Supporting Information). Electrospray ionization mass spectrometry (ESI-MS) on an ABI 3200Q TRAP was used to confirm mass of peptides. Full analytical data of the synthesized peptides are given in the Supporting Information.

Disulfide Bridge Formation in Peptide 1

Pure linear peptide H-Tyr-Cys-His-DPhe-Arg-Trp-Asn-Ala-Phe-Cys-Tyr-NH₂ was dissolved in 20% DMSO in water (1.0 mg/mL) and stirred at room temperature for 24 h. Progress of the disulfide cyclization was monitored by RP-HPLC. The resulting solution was concentrated and purified by RP-HPLC to yield peptide **1** [H-Tyr- ϵ [Cys-His-DPhe-Arg-Trp-Asn-Ala-Phe-Cys]-Tyr-NH₂].

Preparation of Peptides that used Copper Catalyzed Cyclization

The purified linear peptide of interest (1 equiv.), CuSO₄·5H₂O (2 equiv.) and sodium ascorbate (3 equiv.) were added to a 6 mL deoxygenated solution mixture of H₂O-*t*-BuOH (1:1) and was mixed with nitrogen gas for 15 min. In the synthesis of peptides **9** and **14**, 1,3-diethynylbenzene (1 equiv.) and tris(3-hydroxypropyltriazolylmethyl)-amine (1 equiv.) were also added. The mixture was stirred overnight at room temperature under nitrogen atmosphere, concentrated, and then passed through solid-phase extraction (SPE) RP (C18) column with ACN in water. Peptides were purified using semi-preparative HPLC as described above to afford pure peptides.

Preparation of Ruthenium Catalyzed 1,5-disubstituted Triazole Peptides

The appropriate peptide resin was placed in a 25 mL polypropylene reaction vessel (CEM) and swelled in DMF (10 mL) for 30 min while bubbling argon gas. Then the chloro(pentamethylcyclopentadienyl)-(cyclooctadiene)ruthenium (II) (20 mol% of initial loading of the resin) was added to the reaction mixture. In the synthesis of peptides **12** and **16**, 1,3-diethynylbenzene (1 equiv.) was also added to the reaction mixture. The resulting mixture was heated under microwave irradiation for 3 h at 60 °C, 30 W under an argon atmosphere. The resin was cooled and washed with methanol, 2% sodium dithiocarbamate in DMF (v/v), and DMF. Final peptides were cleaved and purified by semi-preparative HPLC to afford purified peptides.

NMR Spectroscopy

The ligand NMR samples were prepared by dissolving 1.6 mg of the purified peptides in a 700 μ L solution containing 480 μ L of CD₃CN and 220 μ L of H₂O. The NMR data were collected at 32°C with a Bruker Avance II 600 MHz spectrometer and a 5-mm CryoProbe in the McKnight Brain Institute's Advanced Magnetic Resonance and Imaging Spectroscopy (AMRIS) facility at the University of Florida. Standard 2D ¹H-¹³C HSQC NMR data were collected, processed, and analyzed.

AlphaScreen™ cAMP Bioassay Studies

Pharmacological characterization of the synthesized peptides at the mMC1R, mMC3R, mMC4R, and mMC5R was performed using the AlphaScreen™ cAMP assay (cat# 676062M, Perkin Elmer Life Sciences). It was performed as described by the manufacturer and described previously by our lab,^{71, 72} but it is also described briefly below.

The peptide ligands were dissolved in DMSO at a stock concentration of 10⁻² M and stored at -20 °C until assayed. HEK-293 cells were stably transfected with the mouse melanocortin receptors using a pCDNA3 expression vector using a calcium phosphate method and G418 selection as previously reported.^{22, 36, 71, 72, 75} These cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% newborn calf serum (NCS) and 1% penicillin/streptomycin at 37°C in a humidified atmosphere of 5% CO₂ and 95% air.

Cells were 70–90% confluent in 10 cm plates on the day of the assay. Stimulation buffer (Hank's Balanced Salt Solution [HBSS 10× [-] sodium bicarbonate] and [-] phenol red, Gibco®), 0.5 mM isobutylmethylxanthine [IBMX], 5 mM HEPES buffer solution [1M, Gibco®], 0.1% bovine serum albumin [BSA] in Milli-Q water, pH=7.4) and the lysis buffer (5mM HEPES buffer solution [1M, Gibco®], 0.1% BSA, 0.3% Tween-20 [aqueous solution 10% w/v] in Milli-Q water, pH=7.4) were prepared on the day of the assay. The cells were dislodged with Versene (Gibco®) at 37°C followed by centrifugation at 800 RPMs for 5 minutes at room temperature (Sorvall Super T21 high speed centrifuge, swinging bucket rotor). The media was aspirated and cells were suspended in Dulbecco's phosphate buffered saline solution (DPBS 1× [-] calcium chloride and [-] magnesium chloride, Gibco®). A 10 μ L aliquot of cell suspension was mixed with 10 μ L Trypan blue dye solution (BioRad), and 10 μ L of this solution was counted manually by hemocytometer. The cells were centrifuged again at 800 RPMs for 5 minutes at room temperature. The cells were re-suspended in stimulation buffer at a concentration of 10 × 10⁶ cells/mL. Anti-cAMP acceptor beads (1.0 unit/well, AlphaScreen™) were added to the cells and 10,000 cells were added to each well of 384-well plate (Optiplate™; PerkinElmer). The cells were stimulated with peptide at the desired in-well concentration in stimulation buffer ranging from 10⁻⁴ to 10⁻¹² M as appropriate or forskolin control (10⁻⁴ M). The plate was then incubated in the dark at room temperature for 2 h.

A three-component mixture of lysis buffer, biotinylated cAMP (1 unit/well, AlphaScreen™), and streptavidin donor bead working solution (1 unit/well, AlphaScreen™) was prepared in the dark at least an hour prior to the addition. Following the 2 h incubation period, the three-component solution was added and mixed under green light to each well. The plate was

incubated for 2 h in a dark at room temperature and then read on the Enspire™ Alpha plate reader using a pre-normalized assay protocol (set by the manufacturer). The assays were performed using duplicate data points and repeated in at least three independent experiments. The potencies and their associated standard errors of mean (SEM), were determined by fitting the data to a nonlinear regression method using the PRISM program (v4.0, GraphPad Inc.).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work has been supported by NIH Grant R01DK091906 (C.H.-L.). Authors would like to thank the National High Magnetic Field Laboratory grant, which is supported by National Science Foundation Cooperative Agreement No. DMR-1157490 and the State of Florida. We would also like to acknowledge the receipt of a 2017 Wallin Neuroscience Discovery Fund Award and acknowledge Dr. Mark Ericson and Dr. Skye Doering for their aid in the preparation of this manuscript.

ABBREVIATIONS

ACTH

Adrenocorticotrophic Hormone

AGRP

Agouti-Related Protein

ASIP

agouti-signaling protein

cAMP

cyclic 5'-adenosine monophosphate

DCM

dichloromethane

DMF

N,N-dimethylformamide

Fmoc

N^α 9-fluorenylmethoxycarbonyl

GPCR

G-Protein Coupled Receptor

MC1R

Melanocortin-1 Receptor

MC2R

Melanocortin-2 Receptor

MC3R

Melanocortin-3 Receptor

MC4R

Melanocortin-4 Receptor

MC5R

Melanocortin-5 Receptor

MCR

Melanocortin Receptor

MeOH

Methanol

MSH

Melanocyte Stimulating Hormone

POMC

Proopiomelanocortin

SEM

Standard Error of the Mean

TFA

Trifluoroacetic acid

 α -MSH

Alpha-Melanocyte Stimulating Hormone

 β -MSH

Beta-Melanocyte Stimulating Hormone

 γ -MSH

Gamma-Melanocyte Stimulating Hormone

 μ M

Micromolar

NDP-MSH (4-Norleucine-7-D-Phenylalanine)Ac-Ser-Tyr-Ser-Nle-Glu-His-DPhe-Arg-Trp-Gly-Lys-Pro-Val-NH₂**References**

1. Irani BG, Holder JR, Todorovic A, Wilczynski AM, Joseph CG, Wilson KR, Haskell-Luevano C. Progress in the development of melanocortin receptor selective ligands. *Curr. Pharm. Des.* 2004; 10:3443–3479. [PubMed: 15579046]
2. Chhajlani V, Wikberg JE. Molecular cloning and expression of the human melanocyte stimulating hormone receptor cDNA. *FEBS Lett.* 1992; 309:417–420. [PubMed: 1516719]

3. Mountjoy KG, Robbins LS, Mortrud MT, Cone RD. The cloning of a family of genes that encode the melanocortin receptors. *Science*. 1992; 257:1248–1251. [PubMed: 1325670]
4. Roselli-Rehfuess L, Mountjoy KG, Robbins LS, Mortrud MT, Low MJ, Tatro JB, Entwistle ML, Simerly RB, Cone RD. Identification of a receptor for gamma melanotropin and other proopiomelanocortin peptides in the hypothalamus and limbic system. *Proc. Natl. Acad. Sci. U. S. A.* 1993; 90:8856–8860. [PubMed: 8415620]
5. Mountjoy KG, Mortrud MT, Low MJ, Simerly RB, Cone RD. Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain. *Mol. Endocrinol.* 1994; 8:1298–1308. [PubMed: 7854347]
6. Gantz I, Konda Y, Tashiro T, Shimoto Y, Miwa H, Munzert G, Watson SJ, DelValle J, Yamada T. Molecular cloning of a novel melanocortin receptor. *J Biol Chem.* 1993; 268:8246–8250. [PubMed: 8463333]
7. Gantz I, Miwa H, Konda Y, Shimoto Y, Tashiro T, Watson SJ, Delvalle J, Yamada T. Molecular-cloning, expression, and gene localization of a 4th melanocortin receptor. *J. Biol. Chem.* 1993; 268:15174–15179. [PubMed: 8392067]
8. Gantz I, Shimoto Y, Konda Y, Miwa H, Dickinson CJ, Yamada T. Molecular cloning, expression, and characterization of a fifth melanocortin receptor. *Biochem. Biophys. Res. Commun.* 1994; 200:1214–1220. [PubMed: 8185570]
9. Bultman SJ, Michaud EJ, Woychik RP. Molecular characterization of the mouse agouti locus. *Cell.* 1992; 71:1195–1204. [PubMed: 1473152]
10. Ollmann MM, Wilson BD, Yang YK, Kerns JA, Chen Y, Gantz I, Barsh GS. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. *Science*. 1997; 278:135–138. [PubMed: 9311920]
11. Butler AA, Kesterson RA, Khong K, Cullen MJ, Pelleymounter MA, Dekoning J, Baetscher M, Cone RD. A unique metabolic syndrome causes obesity in the melanocortin-3 receptor-deficient mouse. *Endocrinology*. 2000; 141:3518–3521. [PubMed: 10965927]
12. Chen AS, Marsh DJ, Trumbauer ME, Frazier EG, Guan XM, Yu H, Rosenblum CI, Vongs A, Feng Y, Cao L, Metzger JM, Strack AM, Camacho RE, Mellin TN, Nunes CN, Min W, Fisher J, Gopal-Truter S, MacIntyre DE, Chen HY, Van der Ploeg LH. Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. *Nat. Genet.* 2000; 26:97–102. [PubMed: 10973258]
13. Fan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD. Role of melanocortinergergic neurons in feeding and the agouti obesity syndrome. *Nature*. 1997; 385:165–168. [PubMed: 8990120]
14. Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, Gu W, Kesterson RA, Boston BA, Cone RD, Smith FJ, Campfield LA, Burn P, Lee F. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. *Cell*. 1997; 88:131–141. [PubMed: 9019399]
15. Chen W, Kelly MA, Opitz-Araya X, Thomas RE, Low MJ, Cone RD. Exocrine gland dysfunction in MC5-R-deficient mice: Evidence for coordinated regulation of exocrine gland function by melanocortin peptides. *Cell*. 1997; 91:789–798. [PubMed: 9413988]
16. Eipper BA, Mains RE. Structure and biosynthesis of pro-adrenocorticotropin/endorphin and related peptides. *Endocr. Rev.* 1980; 1:1–27. [PubMed: 6262069]
17. Smith AI, Funder JW. Proopiomelanocortin processing in the pituitary, central nervous system, and peripheral tissues. *Endocr. Rev.* 1988; 9:159–179. [PubMed: 3286233]
18. Castrucci AM, Hadley ME, Sawyer TK, Wilkes BC, Al-Obeidi F, Staples DJ, De Vaux AE, Dym O, Hintz MF, Riehm JP, Rao KR, Hruby VJ. Alpha-melanotropin: The minimal active sequence in the lizard skin bioassay. *Gen. Comp. Endocrinol.* 1989; 73:157–163. [PubMed: 2537778]
19. Hruby VJ, Wilkes BC, Hadley ME, Al-Obeidi F, Sawyer TK, Staples DJ, de Vaux AE, Dym O, Castrucci AM, Hintz MF, Riehm JP, Rao KR. Alpha-melanotropin: The minimal active sequence in the frog skin bioassay. *J. Med. Chem.* 1987; 30:2126–2130. [PubMed: 2822931]
20. Haskell-Luevano C, Sawyer TK, Hendrata S, North C, Panahinia L, Stum M, Staples DJ, Castrucci AM, Hadley ME, Hruby VJ. Truncation studies of alpha-melanotropin peptides identify tripeptide analogues exhibiting prolonged agonist bioactivity. *Peptides*. 1996; 17:995–1002. [PubMed: 8899819]

21. Ericson MD, Lensing CJ, Fleming KA, Schlasner KN, Doering SR, Haskell-Luevano C. Bench-top to clinical therapies: A review of melanocortin ligands from 1954 to 2016. *Biochim. Biophys. Acta.* 2017; 1863:2414–2435. [PubMed: 28363699]
22. Lensing CJ, Adank DN, Wilber SL, Freeman KT, Schnell SM, Speth RC, Zarth AT, Haskell-Luevano C. A direct in vivo comparison of the melanocortin monovalent agonist Ac-His-DPhe-Arg-Trp-NH₂ versus the bivalent agonist Ac-His-DPhe-Arg-Trp-PEDG20-His-DPhe-Arg-Trp-NH₂: A bivalent advantage. *ACS Chem. Neurosci.* 2017; 8:1262–1278. [PubMed: 28128928]
23. Haskell-Luevano C, Monck EK. Agouti-related protein functions as an inverse agonist at a constitutively active brain melanocortin-4 receptor. *Regul. Pept.* 2001; 99:1–7. [PubMed: 11257308]
24. Nijenhuis WA, Oosterom J, Adan RA. AgRP(83-132) acts as an inverse agonist on the human-melanocortin-4 receptor. *Mol. Endocrinol.* 2001; 15:164–171. [PubMed: 11145747]
25. Irani BG, Xiang Z, Yarandi HN, Holder JR, Moore MC, Bauzo RM, Proneth B, Shaw AM, Millard WJ, Chambers JB, Benoit SC, Clegg DJ, Haskell-Luevano C. Implication of the melanocortin-3 receptor in the regulation of food intake. *Eur. J. Pharmacol.* 2011; 660:80–87. [PubMed: 21199647]
26. Ebihara K, Ogawa Y, Katsuura G, Numata Y, Masuzaki H, Satoh N, Tamaki M, Yoshioka T, Hayase M, Matsuoka N, Aizawa-Abe M, Yoshimasa Y, Nakao K. Involvement of agouti-related protein, an endogenous antagonist of hypothalamic melanocortin receptor, in leptin action. *Diabetes.* 1999; 48:2028–2033. [PubMed: 10512369]
27. Fong TM, Mao C, MacNeil T, Kalyani R, Smith T, Weinberg D, Tota MR, Van der Ploeg LH. ART (protein product of agouti-related transcript) as an antagonist of MC-3 and MC-4 receptors. *Biochem. Biophys. Res. Commun.* 1997; 237:629–631. [PubMed: 9299416]
28. Kiefer LL, Veal JM, Mountjoy KG, Wilkison WO. Melanocortin receptor binding determinants in the agouti protein. *Biochemistry.* 1998; 37:991–997. [PubMed: 9454589]
29. Tota MR, Smith TS, Mao C, MacNeil T, Mosley RT, Van der Ploeg LH, Fong TM. Molecular interaction of agouti protein and agouti-related protein with human melanocortin receptors. *Biochemistry.* 1999; 38:897–904. [PubMed: 9893984]
30. Yang YK, Thompson DA, Dickinson CJ, Wilken J, Barsh GS, Kent SB, Gantz I. Characterization of agouti-related protein binding to melanocortin receptors. *Mol. Endocrinol.* 1999; 13:148–155. [PubMed: 9892020]
31. Ericson MD, Wilczynski A, Sorensen NB, Xiang Z, Haskell-Luevano C. Discovery of a beta-hairpin octapeptide, c[Pro-Arg-Phe-Phe-Dap-Ala-Phe-DPro], mimetic of agouti-related protein(87-132) [AGRP(87-132)] with equipotent mouse melanocortin-4 receptor (mMC4R) antagonist pharmacology. *J. Med. Chem.* 2015; 58:4638–4647. [PubMed: 25898270]
32. Wilczynski A, Wang XS, Joseph CG, Xiang Z, Bauzo RM, Scott JW, Sorensen NB, Shaw AM, Millard WJ, Richards NG, Haskell-Luevano C. Identification of putative agouti-related protein(87-132)-melanocortin-4 receptor interactions by homology molecular modeling and validation using chimeric peptide ligands. *J. Med. Chem.* 2004; 47:2194–2207. [PubMed: 15084118]
33. Haskell-Luevano C, Monck EK, Wan YP, Schentrup AM. The agouti-related protein decapeptide (Yc[CRFFNAFC]Y) possesses agonist activity at the murine melanocortin-1 receptor. *Peptides.* 2000; 21:683–689. [PubMed: 10876051]
34. Wilczynski A, Wilson KR, Scott JW, Edison AS, Haskell-Luevano C. Structure-activity relationships of the unique and potent agouti-related protein (AGRP)-melanocortin chimeric Tyr-c[beta-Asp-His-DPhe-Arg-Trp-Asn-Ala-Phe-Dpr]-Tyr-NH₂ peptide template. *J. Med. Chem.* 2005; 48:3060–3075. [PubMed: 15828845]
35. Jackson PJ, Yu B, Hunrichs B, Thompson DA, Chai B, Gantz I, Millhauser GL. Chimeras of the agouti-related protein: insights into agonist and antagonist selectivity of melanocortin receptors. *Peptides.* 2005; 26:1978–1987. [PubMed: 16009463]
36. Xiang Z, Pogozheva ID, Sorensen NB, Wilczynski AM, Holder JR, Litherland SA, Millard WJ, Mosberg HI, Haskell-Luevano C. Peptide and small molecules rescue the functional activity and agonist potency of dysfunctional human melanocortin-4 receptor polymorphisms. *Biochemistry.* 2007; 46:8273–8287. [PubMed: 17590021]

37. Singh A, Wilczynski A, Holder JR, Witek RM, Dirain ML, Xiang Z, Edison AS, Haskell-Luevano C. Incorporation of a bioactive reverse-turn heterocycle into a peptide template using solid-phase synthesis to probe melanocortin receptor selectivity and ligand conformations by 2D 1H NMR. *J. Med. Chem.* 2011; 54:1379–1390. [PubMed: 21306168]
38. Singh A, Wilczynski A, Holder JR, Witek RM, Dirain ML, Xiang Z, Edison AS, Haskell-Luevano C. Incorporation of a bioactive reverse-turn heterocycle into a peptide template using solid-phase synthesis to probe melanocortin receptor selectivity and ligand conformations by 2D 1H NMR. *J. Med. Chem.* 2011; 54:1379–1390. [PubMed: 21306168]
39. Singh A, Dirain M, Witek R, Rocca JR, Edison AS, Haskell-Luevano C. Structure-activity relationships of peptides incorporating a bioactive reverse-turn heterocycle at the melanocortin receptors: Identification of a 5800-fold mouse melanocortin-3 receptor (mMC3R) selective antagonist/partial agonist versus the mouse melanocortin-4 receptor (mMC4R). *J. Med. Chem.* 2013; 56:2747–2763. [PubMed: 23432160]
40. Singh A, Dirain ML, Wilczynski A, Chen C, Gosnell BA, Levine AS, Edison AS, Haskell-Luevano C. Synthesis, biophysical, and pharmacological evaluation of the melanocortin agonist AST3-88: Modifications of peptide backbone at Trp 7 position lead to a potent, selective, and stable ligand of the melanocortin 4 receptor (MC4R). *ACS Chem. Neurosci.* 2014; 5:1020–1031. [PubMed: 25141170]
41. Gongora-Benitez M, Tulla-Puche J, Albericio F. Multifaceted roles of disulfide bonds. Peptides as therapeutic. *Chem. Rev.* 2014; 114:901–926. [PubMed: 24446748]
42. Gehrman J, Alewood PF, Craik DJ. Structure determination of the three disulfide bond isomers of alpha-conotoxin GI: A model for the role of disulfide bonds in structural stability. *J. Mol. Biol.* 1998; 278:401–415. [PubMed: 9571060]
43. Laboissiere MC, Sturley SL, Raines RT. The essential function of protein-disulfide isomerase is to unscramble non-native disulfide bonds. *J. Biol. Chem.* 1995; 270:28006–28009. [PubMed: 7499282]
44. Limal D, Briand JP, Dalbon P, Jolivet M. Solid-phase synthesis and on-resin cyclization of a disulfide bond peptide and lactam analogues corresponding to the major antigenic site of HIV gp41 protein. *J. Pept. Res.* 1998; 52:121–129. [PubMed: 9727868]
45. Knerr PJ, Tzekou A, Ricklin D, Qu H, Chen H, van der Donk WA, Lambris JD. Synthesis and activity of thioether-containing analogues of the complement inhibitor compstatin. *ACS Chem. Biol.* 2011; 6:753–760. [PubMed: 21520911]
46. Derksen DJ, Stymiest JL, Vederas JC. Antimicrobial leucocin analogues with a disulfide bridge replaced by a carbocycle or by noncovalent interactions of allyl glycine residues. *J. Am. Chem. Soc.* 2006; 128:14252–14253. [PubMed: 17076487]
47. Brik A. Metathesis in peptides and peptidomimetics. *Adv. Synth. Catal.* 2008; 350:1661–1675.
48. Moroder L. Isosteric replacement of sulfur with other chalcogens in peptides and proteins. *J. Pept. Sci.* 2005; 11:187–214. [PubMed: 15782428]
49. Liskamp RM, Rijkers DT, Kruijtz JA, Kemmink J. Peptides and proteins as a continuing exciting source of inspiration for peptidomimetics. *Chembiochem.* 2011; 12:1626–1653. [PubMed: 21751324]
50. Roice M, Johannsen I, Meldal M. High capacity poly(ethylene glycol) based amino polymers for peptide and organic synthesis. *QSAR Comb. Sci.* 2004; 23:662–673.
51. Meldal M, Tornøe CW. Cu-catalyzed azide-alkyne cycloaddition. *Chem. Rev.* 2008; 108:2952–3015. [PubMed: 18698735]
52. Rostovtsev VV, Green LG, Fokin VV, Sharpless KB. A stepwise Huisgen cycloaddition process: Copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes. *Angew. Chem. Int. Ed. Engl.* 2002; 41:2596–2599. [PubMed: 12203546]
53. Tornøe CW, Christensen C, Meldal M. Peptidotriazoles on solid phase: [1,2,3]-triazoles by regioselective copper(I)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides. *J. Org. Chem.* 2002; 67:3057–3064. [PubMed: 11975567]
54. Zhang L, Chen X, Xue P, Sun HH, Williams ID, Sharpless KB, Fokin VV, Jia G. Ruthenium-catalyzed cycloaddition of alkynes and organic azides. *J. Am. Chem. Soc.* 2005; 127:15998–15999. [PubMed: 16287266]

55. Boren BC, Narayan S, Rasmussen LK, Zhang L, Zhao HT, Lin ZY, Jia GC, Fokin VV. Ruthenium-catalyzed azide-alkyne cycloaddition: Scope and mechanism. *J. Am. Chem. Soc.* 2008; 130:14900–14900.
56. Tornøe CW, Sanderson SJ, Mottram JC, Coombs GH, Meldal M. Combinatorial library of peptidotriazoles: Identification of [1,2,3]-triazole inhibitors against a recombinant *Leishmania mexicana* cysteine protease. *J. Comb. Chem.* 2004; 6:312–324. [PubMed: 15132590]
57. Li H, Aneja R, Chaiken I. Click chemistry in peptide-based drug design. *Molecules.* 2013; 18:9797–9817. [PubMed: 23959192]
58. Hanold LE, Oruganty K, Ton NT, Beedle AM, Kannan N, Kennedy EJ. Inhibiting EGFR dimerization using triazolyl-bridged dimerization arm mimics. *PLoS One.* 2015; 10:e0118796. [PubMed: 25790232]
59. Sandomenico A, Celentano V, D'Andrea LD, Palmieri G, Ruvo M. Screening of β -hairpin peptide-engrafted 1,2,3-triazoles to identify APEH enzyme inhibitors. *RSC Adv.* 2015; 5:9965–9972.
60. Celentano V, Diana D, De Rosa L, Romanelli A, Fattorusso R, D'Andrea LD. Beta-hairpin stabilization through an interstrand triazole bridge. *Chem. Commun.* 2012; 48:762–764.
61. Holland-Nell K, Meldal M. Maintaining biological activity by using triazoles as disulfide bond mimetics. *Angew. Chem. Int. Ed. Engl.* 2011; 50:5204–5206. [PubMed: 21472909]
62. Gori A, Wang CI, Harvey PJ, Rosengren KJ, Bhola RF, Gelmi ML, Longhi R, Christie MJ, Lewis RJ, Alewood PF, Brust A. Stabilization of the cysteine-rich conotoxin MrIA by using a 1,2,3-triazole as a disulfide bond mimetic. *Angew. Chem. Int. Ed. Engl.* 2015; 54:1361–1364. [PubMed: 25483297]
63. Empting M, Avrutina O, Meusinger R, Fabritz S, Reinwarth M, Biesalski M, Voigt S, Buntkowsky G, Kolmar H. "Triazole bridge": Disulfide-bond replacement by ruthenium-catalyzed formation of 1,5-disubstituted 1,2,3-triazole. *Angew. Chem. Int. Ed. Engl.* 2011; 50:5207–5211. [PubMed: 21544910]
64. Testa C, Scrima M, Grimaldi M, D'Ursi AM, Dirain ML, Lubin-Germain N, Singh A, Haskell-Luevano C, Chorev M, Rovero P, Papini AM. 1,4-disubstituted-[1,2,3]triazolyl-containing analogues of MT-II: Design, synthesis, conformational analysis, and biological activity. *J. Med. Chem.* 2014; 57:9424–9434. [PubMed: 25347033]
65. Chang CD, Meienhofer J. Solid-phase peptide synthesis using mild base cleavage of N- α -Fluorenylmethyloxycarbonylamino acids, exemplified by a synthesis of dihydrosomatostatin. *Int. J. Pept. Protein Res.* 1978; 11:246–249. [PubMed: 649259]
66. Nielsen CJ, Sjogren CE. The vibrational-spectra, molecular-structure and conformation of organic azides. An abinitio study of hydrazoic acid, azidomethane, azidoethane, azidoethene and azidomethanal. *J. Mol. Struct.: Theochem.* 1987; 35:361–379.
67. Chen FF, Wang F. Electronic structure of the azide group in 3 cent-azido-3 cent-deoxythymidine (AZT) compared to small azide compounds. *Molecules.* 2009; 14:2656–2668. [PubMed: 19633631]
68. Tam A, Arnold U, Soellner MB, Raines RT. Protein prosthesis: 1,5-disubstituted[1,2,3]triazoles as cis-peptide bond surrogates. *J. Am. Chem. Soc.* 2007; 129:12670–12671. [PubMed: 17914828]
69. Hruby VJ, Lu D, Sharma SD, Castrucci AL, Kesterson RA, al-Obeidi FA, Hadley ME, Cone RD. Cyclic lactam α -melanotropin analogues of Ac-Nle4-cyclo[Asp5, D-Phe7,Lys10] α -melanocyte-stimulating hormone-(4–10)-NH₂ with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors. *J. Med. Chem.* 1995; 38:3454–3461. [PubMed: 7658432]
70. Lau YH, de Andrade P, Quah S-T, Rossmann M, Laraia L, Sköld N, Sum TJ, Rowling PJE, Joseph TL, Verma C, Hyvönen M, Itzhaki LS, Venkitaraman AR, Brown CJ, Lane DP, Spring DR. Functionalised staple linkages for modulating the cellular activity of stapled peptides. *Chem. Sci.* 2014; 5:1804–1809.
71. Singh A, Tala SR, Flores V, Freeman K, Haskell-Luevano C. Synthesis and pharmacology of α / β (3)-peptides based on the melanocortin agonist Ac-His-DPhe-Arg-Trp-NH₂ sequence. *ACS Med. Chem. Lett.* 2015; 6:568–572. [PubMed: 26005535]
72. Lensing CJ, Freeman KT, Schnell SM, Adank DN, Speth RC, Haskell-Luevano C. An in vitro and in vivo investigation of bivalent ligands that display preferential binding and functional activity for

different melanocortin receptor homodimers. *J. Med. Chem.* 2016; 59:3112–3128. [PubMed: 26959173]

73. Kann N, Johansson JR, Beke-Somfai T. Conformational properties of 1,4- and 1,5-substituted 1,2,3-triazole amino acids - Building units for peptidic foldamers. *Org. Biomol. Chem.* 2015; 13:2776–2785. [PubMed: 25605623]
74. Kaiser E, Colescott RL, Bossinger CD, Cook PI. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. *Anal. Biochem.* 1970; 34:595–598. [PubMed: 5443684]
75. Chen CA, Okayama H. Calcium phosphate-mediated gene transfer: A highly efficient transfection system for stably transforming cells with plasmid DNA. *BioTechniques.* 1988; 6:632–638. [PubMed: 3273409]

Figure 1.

a) Previously reported AGRP chimeric peptide template. b) Non-natural amino acid building blocks Fmoc-L-azidoalanine (Fmoc-Aza-OH), Fmoc-L-propargylglycine (Fmoc-Pra-OH), and Fmoc-L-azidoornithine (Fmoc-Orn(N₃)-OH).

Figure 2. Illustration of the agonist pharmacology of compounds **1–3** and **6** at the mMC1R, mMC3R, mMC4R and mMC5R. The AlphaScreen™ assay is a competition assay with loss of signal resulting from increased agonist activity. Hence, the concentration-activity curves were normalized to the maximal response of NDP-MSH for illustration purposes.

Scheme 1.

Synthesis of 1,4-disubstituted 1,2,3-triazole bridged peptide **3**^a

^aReagents and conditions: (i) Fmoc-SPPS; (ii) 91% TFA, scavengers; (iii) copper(II) sulfate pentahydrate, sodium ascorbate, $\text{H}_2\text{O-}t\text{-BuOH}$ (1:1), rt, overnight.

Scheme 2.

Synthesis of 1,5-disubstituted 1,2,3-triazole bridged peptide **6**^a

^aReagents and conditions: (i) Fmoc-SPPS; (ii) chloro(pentamethylcyclopentadienyl)(cyclo-octadiene)-ruthenium (II), MW, 60 °C, 3 h; (iii) Fmoc-SPPS; (iv) 91% TFA, scavengers.

Scheme 3.

Synthesis of 1,4-disubstituted 1,2,3-bis-triazole containing peptide **9**^a

^aReagents and conditions: (i) Fmoc-SPPS; (ii) 91% TFA, scavengers; (iii) 1,3-diethynylbenzene, copper(II) sulfate pentahydrate, tris(3-hydroxypropyltriazolylmethyl)amine, sodium ascorbate, $\text{H}_2\text{O-}t\text{-BuOH}$ (1:1), rt, overnight.

Scheme 4.

Synthesis of 1,5-disubstituted 1,2,3-bis-triazole containing peptide **12^a**

^aReagents and conditions: (i) Fmoc-SPPS; (ii) 1,3-diethynylbenzene, chloro(pentamethylcyclo-pentadienyl)(cyclooctadiene)ruthenium (II), MW, 60 °C, 3 h; (iii) 20% piperidine in DMF; (iv) 91% TFA, scavengers.

Scheme 5.

Synthesis of 1,4-disubstituted 1,2,3-bis-triazole bridged peptide **14**^a

^aReagents and conditions: (i) Fmoc-SPPS; (ii) 91% TFA, scavengers; (iii) 1,3-diethynylbenzene, copper(II) sulfate pentahydrate, tris(3-hydroxypropyltriazolylmethyl)amine, sodium ascorbate, H₂O-*t*-BuOH (1:1), rt, overnight.

Scheme 6.

Synthesis of 1,5-disubstituted 1,2,3-bis-triazole bridged peptide **16**^a

^aReagents and conditions: (i) Fmoc-SPPS; (ii) 1,3-diethynylbenzene, chloro(pentamethylcyclo-pentadienyl)(cyclooctadiene)ruthenium (II), MW, 60 °C, 3 h; (iii) 20% piperidine in DMF; (iv) 91% TFA, scavengers.

Table 1

Peptide number and sequence

Peptide	Sequence
1	<p>Tyr-Cys-His-DPhe-Arg-Trp-Asn-Ala-Phe-Cys-Tyr-NH₂</p>
2	
3	
6	
7	
8	

12

13

14

16

Table 2
Summary of the Agonist Pharmacology of Peptides **1–3** and **6** Evaluated at the Mouse Melanocortin Receptors

Peptide	mMC1R EC ₅₀ (nM)	Fold diff	mMC3R EC ₅₀ (nM)	Fold diff	mMC4R EC ₅₀ (nM)	Fold diff	mMC5R EC ₅₀ (nM)	Fold diff
NDP-MSH	0.02 ± 0.008		0.24 ± 0.04		0.34 ± 0.09		0.39 ± 0.08	
1	0.14 ± 0.01	1	2.2 ± 0.58	1	0.43 ± 0.13	1	2.4 ± 0.31	1
2	58 ± 6.3	414	51 ± 9.3	23	29 ± 5.2	46	20 ± 3.8	8
3	5.8 ± 2.0	41	28 ± 5.4	13	6.0 ± 1.0	14	16 ± 0.66	6.6
6	4.0 ± 2.4	29	6.4 ± 2.0	3	2.0 ± 0.47	4.6	3.6 ± 1.1	1.5

^a AlphaScreen™ technology was used to determine relative potency of compounds to induce cAMP signaling. The indicated errors represent the standard error of the mean (SEM) determined from at least three independent experiments.

Summary of the Agonist Pharmacology of Peptides **7**, **9** and **12** Evaluated at the Mouse Melanocortin Receptors**Table 3**

Peptide	mMC1R EC ₅₀ (nM)	Fold diff	mMC3R EC ₅₀ (nM)	Fold diff	mMC4R EC ₅₀ (nM)	Fold diff	mMC5R EC ₅₀ (nM)	Fold diff
NDP-MSH	0.02 ± 0.008		0.24 ± 0.04		0.34 ± 0.09		0.39 ± 0.08	
1	0.14 ± 0.01	1	2.2 ± 0.58	1	0.43 ± 0.13	1	2.4 ± 0.31	1
7	5.0 ± 0.24	36	59 ± 5.8	27	16.0 ± 5.0	37	20.0 ± 2.0	8
9	802 ± 227	5728	1462 ± 245	665	1522 ± 328	3540	294 ± 4.8	122
12	116 ± 40	829	404 ± 52	184	142 ± 30	330	107 ± 17	45

^a AlphaScreen™ technology was used to determine relative potency of compounds to induce cAMP signaling. The indicated errors represent the standard error of the mean (SEM) determined from at least three independent experiments.

Table 4

Summary of the Agonist Pharmacology of Peptides **13**, **14** and **16** Evaluated at the Mouse Melanocortin Receptors

Peptide	mMC1R EC ₅₀ (nM)	Fold diff	mMC3R EC ₅₀ (nM)	Fold diff	mMC4R EC ₅₀ (nM)	Fold diff	mMC5R EC ₅₀ (nM)	Fold diff
NDP-MSH	0.02 ± 0.008		0.24 ± 0.04		0.34 ± 0.09		0.39 ± 0.08	
1	0.14 ± 0.01	1	2.2 ± 0.58	1	0.43 ± 0.13	1	2.4 ± 0.31	1
13	138 ± 18	986	674 ± 162	306	414 ± 54	963	36 ± 7.0	15
14	317 ± 9	2264	1944 ± 687	884	971 ± 213	2258	229 ± 52	95
16	570 ± 153	4071	2744 ± 706	1247	539 ± 154	1253	80 ± 26	33

^a AlphaScreen™ technology was used to determine relative potency of compounds to induce cAMP signaling. The indicated errors represent the standard error of the mean (SEM) determined from at least three independent experiments.